The FDA has approved Cipla's nintedanib capsules as a new generic version of Ofev for treating idiopathic pulmonary fibrosis ...

The PFF's strategic plan includes several initiatives to make the community more inclusive of all forms of ILD, writes columnist Sam Kirton.

An IPF diagnosis left columnist Sam Kirton feeling lost, but thanks to several "navigation tools," he eventually found his way.

Columnist Kylene Henderson likes to think of her husband, Donnie, as Iron Man, given his use of supplemental oxygen to thrive ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Living with a chronic and progressive disease like pulmonary fibrosis (PF) can be challenging, and there are many issues a person with PF needs to consider, including lifestyle changes, coping with ...

Clinical trials are in-human studies aimed at gathering a variety of information about different aspects of disease and health conditions. Many clinical trials are designed to evaluate the safety and ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).